Alector (ALEC)
NASDAQ:ALEC
Want to see ALEC full AI Analyst Report?
ALEC Stock Chart & Stats
$2.57
-$0.09(-4.55%)
At close: 4:00 PM EST
$2.57
-$0.09(-4.55%)
Day’s Range― - ―
52-Week Range$1.09 - $3.40
Previous CloseN/A
Volume194.31K
Average Volume (3M)703.83K
Market Cap
$194.29M
Enterprise Value$130.78M
Total Cash (Recent Filing)$206.51M
Total Debt (Recent Filing)$34.55M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Jul 30, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding111,025,185
10 Day Avg. Volume553,876
30 Day Avg. Volume703,828
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.24
Price to Sales (P/S)7.63
P/FCF Ratio-0.87
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue7.10
Enterprise Value/Gross Profit-11.60
Enterprise Value/Ebitda-1.12
Forecast
1Y Price Target
$3.63Price Target Upside41.05% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)-0.94
Revenue Forecast (FY)$6.98M
Bulls Say, Bears Say
Bulls Say
High Gross MarginAlector's ~82% TTM gross margin indicates product-level economics are strong and scalable if a therapy reaches commercialization. This durable advantage means future revenues can translate to high incremental profits once fixed R&D and SG&A are controlled, supporting long-term margin sustainability.
Focused Immuno‑neurology PipelineAlector's concentrated platform in immuno‑neurology targets large unmet needs (Alzheimer’s, FTD) and leverages antibody programs. This specialization creates durable competitive positioning, platform learning effects, and partner interest that can drive long-term value beyond any single trial outcome.
Financing Optionality Via ATM ProgramThe $125M at-the-market facility provides structural financing flexibility to fund R&D, manufacturing and operations without immediate dilution. This ongoing optionality improves runway management and strategic choices over months, reducing near-term liquidity pressure while preserving the ability to raise capital opportunistically.
Bears Say
Sustained Cash BurnPersistently negative operating and free cash flow (~-$173M TTM) indicates the business depends on external financing to sustain development. Over a multi-month horizon this elevates dilution and refinancing risk and constrains strategic optionality unless spending is materially reduced or financing secured.
Rising Leverage And Equity ErosionDebt-to-equity rising to 3.33 (TTM) reflects equity erosion and weaker balance sheet resilience. Elevated leverage limits financial flexibility, raises refinancing and covenant risks, and increases the cost of capital — all structural constraints on executing long-term development plans.
Weak Revenue And Profitability TrajectoryDeclining revenues and extremely negative margins (net margin ~-681%) show lack of commercial cash generation and persistent operating losses. Over the medium term this undermines self-funding capacity, forces reliance on partnerships or capital markets, and heightens the risk that pipeline investments cannot be fully sustained.
Alector News
ALEC FAQ
What was Alector’s price range in the past 12 months?
Alector lowest stock price was $1.09 and its highest was $3.40 in the past 12 months.
What is Alector’s market cap?
Alector’s market cap is $194.29M.
When is Alector’s upcoming earnings report date?
Alector’s upcoming earnings report date is Jul 30, 2026 which is in 39 days.
How were Alector’s earnings last quarter?
Alector released its earnings results on May 07, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.078.
Is Alector overvalued?
According to Wall Street analysts Alector’s price is currently Undervalued.
Does Alector pay dividends?
Alector does not currently pay dividends.
What is Alector’s EPS estimate?
Alector’s EPS estimate is -0.22.
How many shares outstanding does Alector have?
Alector has 111,025,185 shares outstanding.
What happened to Alector’s price movement after its last earnings report?
Alector reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went down -13.934%.
Which hedge fund is a major shareholder of Alector?
Currently, no hedge funds are holding shares in ALEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alector Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.63 (41.05% Upside)
$3.63 (41.05% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 94.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $221.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.86%
12-Months-Change
Fundamentals
Return on Equity
-295.17%
Trailing 12-Months
Asset Growth
-41.24%
Trailing 12-Months
Company Description
Alector
Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering new treatments for neurodegenerative disorders. A key program in its pipeline is AL001, a humanized recombinant monoclonal antibody currently undergoing Phase III clinical trials. This investigational therapy targets a range of severe conditions, including frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Additionally, AL101 is progressing through Phase I clinical trials for general neurodegenerative diseases, with a specific focus on Alzheimer's and Parkinson's. Further bolstering its Alzheimer's portfolio, Alector is evaluating AL002 in Phase II studies and AL003 in Phase I studies, both aimed at addressing Alzheimer's disease. In earlier-stage development, the company is also developing AL044, which targets the MS4A4A gene, identified as a risk factor for Alzheimer's disease. Alector has forged key partnerships to advance its mission. It collaborates with Adimab, LLC on antibody research and development. Furthermore, a significant strategic alliance with GlaxoSmithKline plc (GSK) focuses on the joint development and commercialization of monoclonal antibodies, specifically AL001 and AL101, for neurodegenerative conditions. Established in 2013, Alector's headquarters are located in South San Francisco, California.
ALEC Stock 12 Month Forecast
Average Price Target
$3.63
▲(41.05% Upside)
Technical Analysis
Ownership Overview
7.29% Insiders
11.50% Mutual Funds
38.59% Other Institutional Investors
33.17% Public Companies and
Individual Investors